TNF and myeloid sarcoma: However, despite the pro-inflammatory actions of TNF-α, the use of anti-TNF-α monoclonal antibodies in MS patients, in addition to being ineffective, promotes an unexpected worsening of the disease [81], indicating that this cytokine also plays a protective role.